An unexpected finding in preclinical platelet studies could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers.
An unexpected finding in preclinical platelet studies could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers.